関連する実験動画
Updated: Feb 22, 2026

04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.9K
組織性硬化症における薬剤開発:注目すべき新しい治療法
Veronica Batani1,2,3, Jelena Colic4,5, Cristina Scaletti6
1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano, Italy.
Expert review of clinical immunology
|February 21, 2026
まとめ
系統性硬化症 (SSc) の新しい治療法は,免疫機能の調節不全,線維症,血管病変を標的としています. 病気の成功的な改変には,同時に炎症,線維性改造,血管損傷に対処することが必要です.
科学分野:
- レウマトロジーの病理学
- 免疫学 免疫学とは
- 薬理学 薬理学とは
背景:
- システミック硬化症 (SSc) は,並列の免疫機能不調,線維症,血管病を伴う.
- 現在の理解は,これらの病理学的領域の相互接続性を強調しています.
研究 の 目的:
- 臨床開発におけるSScの新興治療戦略をレビューする.
- 臨床前および翻訳的証拠を,現在進行中の医薬品開発パイプラインと結びつける.
- 機械的洞察が新しいSSc治療をどのように導いているかを示すために.
主な方法:
- PubMed/MEDLINE,ClinicalTrials.gov,およびEudraCTの文献検索は2025年10月までとなっている.
- 英語の出版物に集中する.
- メカニズム的洞察を治療戦略と結びつける証拠の合成.
主要な成果:
- 細胞ベースの免疫療法の出現.
- 二固有の抗体の開発.
- 生まれながらの免疫を標的とする次世代の小分子の開発.
結論:
- 新しい治療法は,適応免疫を超えて,先天的免疫を調節する.
- 効果的なSSc治療には,同時に炎症,線維症,血管損傷を抑える必要があります.
- 機械的洞察は,SScの薬物パイプラインの再構築に不可欠です.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
583
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
583
Autoimmune Disorders
2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610
Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
Rheumatic Heart Disease III: Medical Management
401
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
401
Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K

